Skip to main content

Research Repository

Advanced Search

SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins

Mycroft-West, Courtney J.; Su, Dunhao; Li, Yong; Guimond, Scott E.; Rudd, Timothy R.; Elli, Stefano; Miller, Gavin; Nunes, Quentin M.; Procter, Patricia; Bisio, Antonella; Forsyth, Nicholas R.; Turnbull, Jeremy E.; Guerrini, Marco; Fernig, David G.; Yates, Edwin A.; Lima, Marcelo A.; Skidmore, Mark A.

Authors

Courtney J. Mycroft-West

Dunhao Su

Yong Li

Timothy R. Rudd

Stefano Elli

Quentin M. Nunes

Patricia Procter

Antonella Bisio

Nicholas R. Forsyth

Marco Guerrini

David G. Fernig

Edwin A. Yates



Abstract

The dependence of the host on the interaction of hundreds of extracellular proteins with the cell surface glycosaminoglycan heparan sulphate (HS) for the regulation of homeostasis is exploited by many microbial pathogens as a means of adherence and invasion. The closely related polysaccharide heparin, the widely used anticoagulant drug, which is structurally similar to HS and is a common experimental proxy, can be expected to mimic the properties of HS. Heparin prevents infection by a range of viruses when added exogenously, including S-associated coronavirus strain HSR1 and inhibits cellular invasion by SARS-CoV-2. We have previously demonstrated that unfractionated heparin binds to the Spike (S1) protein receptor binding domain, induces a conformational change and have reported the structural features of heparin on which this interaction depends. Furthermore, we have demonstrated that enoxaparin, a low molecular weight clinical anticoagulant, also binds the S1 RBD protein and induces conformational change. Here we expand upon these studies, to a wide range of low molecular weight heparins and demonstrate that they induce a variety of conformational changes in the SARS-CoV-2 RBD. These findings may have further implications for the rapid development of a first-line therapeutic by repurposing low molecular weight heparins, as well as for next-generation, tailor-made, GAG-based antiviral agents, against SARS-CoV-2 and other members of the Coronaviridae .

Citation

Mycroft-West, C. J., Su, D., Li, Y., Guimond, S. E., Rudd, T. R., Elli, S., …Skidmore, M. A. SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins. arXiv, https://doi.org/10.1101/2020.04.29.068486

Journal Article Type Article
Online Publication Date Apr 29, 2020
Deposit Date Jun 16, 2023
Journal arXiv
Print ISSN 2331-8422
Publisher Cornell University
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1101/2020.04.29.068486